Novel Benzyl-Piperidine antifungal agents to treat intractable Mucorales infections
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $299,946
Sep 22, 2025 – Aug 31, 2027
Solicitation PA24-247 (2024) · Topic NIAID · Research partner: DARTMOUTH COLLEGE
Development of well tolerated novel Inhibitors of drug resistant CMV
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $298,582
Aug 8, 2025 – Jul 31, 2027
Solicitation PA24-245 (2024) · Topic NIAID
Discovery of Bunyaviral Endonuclease Inhibitors for Anti Viral
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2025 · $977,449
May 16, 2025 – Apr 30, 2028
Solicitation PA24-247 (2024) · Topic R42 · Research partner: UNIVERSITY OF WASHINGTON
Proof of concept experiments for T3SS inhibitors against burn wound infections
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2024 · $600,000
Apr 12, 2024 – Mar 31, 2026
Solicitation PA23-232 (2023) · Topic 41 · Research partner: MASSACHUSETTS GENERAL HOSPITAL
Development of antibody drug conjugates as pan-filo antivirals
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $586,708
Aug 21, 2023 – Jul 31, 2025
Solicitation PA22-176 (2022) · Topic NIAID
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $568,625
Aug 12, 2022 – Jul 31, 2024
Solicitation PA21-262 (2021) · Topic NIAID · Research partner: WASHINGTON UNIVERSITY
Type 3 secretion system inhibitors to treat Pseudomonas aeruginosa keratitis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $300,156
Jul 1, 2022 – Jun 30, 2023
Solicitation PA21-259 (2021) · Topic 100
Development of Filociclovir for the Treatment of Ocular Adenoviral Infections and Keratoconjunctivitis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2021 · $1,462,324
Jun 1, 2021 – May 31, 2023
Solicitation PA20-260 (2020) · Topic 100
Screening for rAAV transduction enhancers
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2021 · $2,974,481
Feb 3, 2021 – Jan 31, 2024
Solicitation PA19-272 (2019) · Topic NIAID
Development of a novel broad-spectrum inhibitor of non-polio enteroviruses associated with acute flaccid myelitis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $585,191
Sep 8, 2020 – Aug 31, 2022
Solicitation PA19-272 (2019) · Topic NIAID
Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $599,449
Aug 1, 2020 – Jul 31, 2022
Solicitation PA18-575 (2018) · Topic NIAID · Research partner: UNIVERSITY OF MASSACHUSETTS AMHERST
Development of a New Class of Hepatitis B Virus Inhibitors that Induce a Novel Defective Nucleocapsid Phenotype
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $596,806
Jul 21, 2020 – Jun 30, 2022
Solicitation PA19-272 (2019) · Topic NIAID
Discovery of Enterovirus D68 2A protease inhibitors for antiviral therapy
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $600,000
Dec 9, 2019 – Nov 30, 2021
Solicitation PA18-574 (2018) · Topic NIAID
Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $2,996,357
Aug 21, 2019 – Jul 31, 2022
Solicitation PA18-574 (2018) · Topic NIAID
Optimization of novel pyranopyridine efflux pump inhibitors
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $2,968,757
Aug 20, 2019 – Jul 31, 2022
Solicitation PA18-574 (2018) · Topic NIAID
Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $2,974,411
Dec 14, 2018 – Nov 30, 2021
Solicitation PA18-574 (2018) · Topic NIAID
Novel Small Molecule Therapeutics Inhibiting Zika Virus Infection
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $597,627
Sep 4, 2018 – Aug 31, 2020
Solicitation PA17-302 (2017) · Topic NIAID
Discovery of Zika virus therapeutics using a replicon assay
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $584,970
Aug 13, 2018 – Jul 31, 2020
Solicitation PA16-303 (2016) · Topic R · Research partner: UNIVERSITY OF TEXAS MED BR GALVESTON
EF-Tu binding Tetrazoles targeting MDR Neisseria gonorrhoeae
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $596,852
Aug 1, 2018 – Jul 31, 2020
Solicitation PA17-302 (2017) · Topic NIAID
Synergistic panfiloviral entry inhibiting antibody drug conjugates
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $600,000
Feb 8, 2018 – Jan 31, 2021
Solicitation PA17-302 (2017) · Topic R
Inhibitors of virus glycoprotein-LAMP1 receptor binding for Lassa virus therapy
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $595,561
Jan 15, 2018 – Dec 31, 2020
Solicitation PA16-302 (2016) · Topic NIAID
Development of small molecule TLR5 inhibitors for rheumatoid arthritis therapy
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $432,693
Sep 1, 2017 – Jun 30, 2020
Solicitation PAR16-375 (2016) · Topic NIA
Aminospectinomycin antibacterials for the treatment of antibiotic-resistant gonorrhea and other bacterial STDs
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $585,875
Aug 18, 2017 – Jul 31, 2019
Solicitation PA15-269 (2015) · Topic NIAID
Inhibitors of Pseudomonas aeruginosa efflux pumps to combat multi-drug resistance
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $594,140
Jun 1, 2017 – May 31, 2020
Solicitation PA16-302 (2016) · Topic NIAID
Screening for rAAV transduction enhancers
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $590,607
Jan 27, 2017 – Dec 31, 2019
Solicitation PA15-269 (2015) · Topic NIAID
Showing the 25 most recent of 88 awards.
